BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37489000)

  • 1. A comparison of loco-regional relapse pattern in HPV positive vs negative oropharyngeal cancers following radiotherapy; relation to pretreatment FDG-PET and radiotherapy target volumes.
    Håkansson K; Lindegaard AM; Bernsdorf M; Gothelf A; Kristensen CA; Specht L; Friborg J; Vogelius I
    Acta Oncol; 2023 Sep; 62(9):1028-1035. PubMed ID: 37489000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.
    Schouten CS; Hakim S; Boellaard R; Bloemena E; Doornaert PA; Witte BI; Braakhuis BJ; Brakenhoff RH; Leemans CR; Hoekstra OS; de Bree R
    Head Neck; 2016 Apr; 38(4):529-35. PubMed ID: 25352335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.
    Leclerc M; Lartigau E; Lacornerie T; Daisne JF; Kramar A; Grégoire V
    Radiother Oncol; 2015 Jul; 116(1):87-93. PubMed ID: 26088157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning.
    Chen TM; Chen WM; Chen M; Shia BC; Wu SY
    J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):14. PubMed ID: 36782296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Rosen BS; Wilkie JR; Sun Y; Ibrahim M; Casper KA; Miller JE; Chotchutipan T; Stucken CL; Bradford C; Prince MEP; Rosko AJ; Malloy KM; McLean SA; Chinn SB; Shuman AG; Spector ME; Swiecicki PL; Worden FP; Shah JL; Schonewolf CA; Chapman CH; Eisbruch A; Mierzwa ML
    Radiother Oncol; 2021 Feb; 155():174-181. PubMed ID: 33069764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
    Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224).
    Saksø M; Mortensen LS; Primdahl H; Johansen J; Kallehauge J; Hansen CR; Overgaard J
    Radiother Oncol; 2020 Oct; 151():126-133. PubMed ID: 32805273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of Human Papillomavirus Status and Treatment on the Positive Predictive Value of Post-radiotherapy
    Zhou S; Chan C; Lau YC; Rulach R; Dyab H; Hendry F; Wilson C; Schipani S; Lamb C; Grose D; James A; Maxfield C; Dempsey MF; Paterson C
    Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e699-e707. PubMed ID: 37798198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of [
    Pisani C; Vigna L; Mastroleo F; Loi G; Amisano V; Masini L; Deantonio L; Aluffi Valletti P; Sacchetti G; Krengli M
    Radiat Oncol; 2021 Mar; 16(1):57. PubMed ID: 33743759
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    van den Bosch S; Doornaert PAH; Dijkema T; Zwijnenburg EM; Verhoef LCG; Hoeben BAW; Kasperts N; Smid EJ; Terhaard CHJ; Kaanders JHAM
    Radiother Oncol; 2020 Jan; 142():107-114. PubMed ID: 31439447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Zhou S; Chan C; Rulach R; Dyab H; Hendry F; Maxfield C; Dempsey MF; James A; Grose D; Lamb C; Schipani S; Wilson C; Cheng Lau Y; Paterson C
    Oral Oncol; 2022 May; 128():105870. PubMed ID: 35447564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma.
    Gupta T; Chatterjee A; Rangarajan V; Purandare N; Arya S; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal JP
    Q J Nucl Med Mol Imaging; 2022 Jun; 66(2):162-170. PubMed ID: 31496204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic optimization in head and neck radiotherapy planning: Advocacy for
    Nevesny S; Flaus A; Ailloud A; Sotton S; Prevot N; Guy JB; Magné N
    Bull Cancer; 2022 Dec; 109(12):1262-1268. PubMed ID: 36283891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers.
    Rulach R; Zhou S; Hendry F; Stobo D; James A; Dempsey MF; Grose D; Lamb C; Schipani S; Rizwanullah M; Wilson C; Paterson C
    Oral Oncol; 2019 Oct; 97():76-81. PubMed ID: 31437587
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Jo KH; Kim J; Cho H; Kang WJ; Lee SK; Sohn B
    Yonsei Med J; 2023 Dec; 64(12):738-744. PubMed ID: 37992746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake.
    Due AK; Vogelius IR; Aznar MC; Bentzen SM; Berthelsen AK; Korreman SS; Loft A; Kristensen CA; Specht L
    Radiother Oncol; 2014 Jun; 111(3):360-5. PubMed ID: 24993331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of PET-CT in Newly Diagnosed HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Lee J; Davis SJ; Amin SN; Rohde SL; Kim YJ
    Ann Otol Rhinol Laryngol; 2023 Oct; 132(10):1133-1139. PubMed ID: 36453776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodality imaging with CT, MR and FDG-PET for radiotherapy target volume delineation in oropharyngeal squamous cell carcinoma.
    Bird D; Scarsbrook AF; Sykes J; Ramasamy S; Subesinghe M; Carey B; Wilson DJ; Roberts N; McDermott G; Karakaya E; Bayman E; Sen M; Speight R; Prestwich RJ
    BMC Cancer; 2015 Nov; 15():844. PubMed ID: 26530182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.